Hwang K C, Gray C D, Sweet W E, Moravec C S, Im M J
Department of Molecular Cardiology, Cleveland Clinic Foundation, OH 44195, USA.
Circulation. 1996 Aug 15;94(4):718-26. doi: 10.1161/01.cir.94.4.718.
We recently demonstrated that Gh, which transfers the signal from the alpha 1-adrenergic receptor to the 69-kD phospholipase C, is the previously identified tissue-type transglutaminase (TGase II). The alpha 1-adrenergic receptor mediates actions of the sympathetic nervous system, including cardiac, arteriolar, and smooth muscle contractions. In human cardiac tissue, the expression of the alpha 1-adrenergic receptor is increased under pathophysiological conditions, but changes in the physiological response are small. Therefore, it has been suggested that the other components involved in the alpha 1-adrenergic receptor-mediated signaling pathway are probably altered.
Immunological and biochemical studies with nonfailling and failing human heart tissues revealed that the GTP-binding and TGase activities of human heart TGase II (hhG alpha n) are downregulated in both ischemic and dilated cardiomyopathic human heart. In ischemic cardiomyopathy, the alpha 1-adrenergic receptor number increased twofold (27.0 fmol/mg) compared with the nonfailing (12.8 fmol/mg) and the dilated cardiomyopathic (15.6 fmol/mg) heart tissues, but the coupling of hhG alpha h with the alpha 1-adrenergic receptor did not increase. The intrinsic activity of hhG alpha h, was greatly decreased in membrane fractions, whereas the cytosolic TGase activity was not changed. In the dilated cardiomyopathic human heart, these intrinsic enzyme activities of hhG alpha h were also downregulated in the membrane fraction, whereas the amount of hhG alpha h protein was greatly increased (2.8-fold) compared with the nonfailing heart.
The results of the present study clearly demonstrate that the alpha 1-adrenergic receptor in human heart couples with Gh (TGase II) and indicate that downregulation of hhG alpha h activity is associated with human cardiac failure but that the mechanism differs between ischemic and dilated cardiomyopathies.
我们最近证实,将信号从α1 - 肾上腺素能受体传递至69-kD磷脂酶C的Gh是先前鉴定出的组织型转谷氨酰胺酶(TGase II)。α1 - 肾上腺素能受体介导交感神经系统的作用,包括心脏、小动脉和平滑肌收缩。在人类心脏组织中,α1 - 肾上腺素能受体的表达在病理生理条件下会增加,但生理反应的变化很小。因此,有人提出α1 - 肾上腺素能受体介导的信号通路中涉及的其他成分可能发生了改变。
对非衰竭和衰竭的人类心脏组织进行的免疫学和生化研究表明,人类心脏TGase II(hhGαn)的GTP结合和TGase活性在缺血性和扩张型心肌病患者的心脏中均下调。在缺血性心肌病中,与非衰竭(12.8 fmol/mg)和扩张型心肌病(15.6 fmol/mg)心脏组织相比,α1 - 肾上腺素能受体数量增加了两倍(27.0 fmol/mg),但hhGαh与α1 - 肾上腺素能受体的偶联并未增加。hhGαh的内在活性在膜组分中大幅降低,而胞质TGase活性未改变。在扩张型心肌病患者的心脏中,hhGαh的这些内在酶活性在膜组分中也下调,而与非衰竭心脏相比,hhGαh蛋白的量大幅增加(2.8倍)。
本研究结果清楚地表明,人类心脏中的α1 - 肾上腺素能受体与Gh(TGase II)偶联,并表明hhGαh活性下调与人类心力衰竭有关,但缺血性和扩张型心肌病的机制不同。